Internal FDA Fighting on Sarepta Bad Omen for Stem Cell Oversight?
The FDA caused major controversy by approving the drug Exondys 51 from Sarepta Therapeutics for treating Duchenne muscular dystrophy over the recommendations of a scientific panel it convened that had voted 7-3 against approval. Is this contentious Sarepta approval serve as a sign of how the FDA will deal with stem cells moving forward? Will the FDA approval, which […]
Internal FDA Fighting on Sarepta Bad Omen for Stem Cell Oversight? Read More »